Cellectis vs Editas Medicine
CLLS and EDIT side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How CLLS and EDIT compare
Cellectis grew revenue faster over the last twelve months (75.8% versus 7.4% for Editas Medicine).
Cellectis keeps more of each dollar of sales as profit, with a net margin of −92.7% compared with −145% at Editas Medicine.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | CLLS | EDIT |
|---|---|---|
| Size and price | ||
| Market cap | – | $366M |
| Share price | $1.38 | $2.38 |
| Change, 1 year | −61.1% | −5.6% |
| Change, 5 years | −84.5% | −93.3% |
| Beta (5Y) | 2.09 | 2.19 |
| Employees | 229 | 87 |
| StockData Score | ||
| Total score | 3 | 3 |
| Valuation score | 0 | 0 |
| Growth score | 2 (better) | 1 |
| Performance score | 1 | 1 |
| Health score | 0 | 1 (better) |
| Dividend score | 0 | 0 |
| Valuation | ||
| P/S | – | 7.3× |
| P/B | – | 4.3× |
| FCF yield | – | −30.2% |
| Fair value | – | $1.62 |
| Margin of safety | – | −47.2% |
| Growth | ||
| Revenue growth (TTM) | 75.8% (better) | 7.4% |
| Revenue growth, 5Y average | 7.4% (better) | −14.9% |
| Profitability | ||
| Gross margin | 100% | – |
| Operating margin | −45.3% (better) | −152% |
| Net margin | −92.7% (better) | −145% |
| FCF margin | −57.2% (better) | −222% |
| Return on equity | −97.8% (better) | −147% |
| Return on invested capital | −122% | – |
| Financial health | ||
| Debt / equity | – | 0.67 |
| Interest coverage | −0.6× (better) | −10.6× |
| Current ratio | – | 2.82 |
| Altman Z-score | – | −9.39 |
| Piotroski F-score | 3 (better) | 1 |
| Dividends and buybacks | ||
| Buyback yield | – | −36.6% |
| Shareholder yield | – | −36.6% |
| Ownership | ||
| Held by institutions | 9.4% | 78.3% |
| Held by insiders | 53.4% | 0.45% |
| Insider net buying, 12 months | – | −$107K |
| Short interest, % of float | – | 25.3% |
Go deeper
- CLLS stock overview
- CLLS income statement
- CLLS valuation and score
- EDIT stock overview
- EDIT income statement
- EDIT valuation and score
For information only, not investment advice. Check the source filings before relying on any figure.